Short term
Trade view / 21 June 2017 at 13:03 GMT

UPDATE: Pfizer options trade approaches target —#SaxoStrats

Product Manager, Options Trader, Educator
Instrument: PFE:xnys
Price target: 34.75
Market price: 33.56

We introduced on June 1 a call option trade on shares of NYSE-listed global biopharmaceutical company Pfizer to take advantage of a rebound. 

Management and risk description

The New York Stock Exchange biotechnology index reached a fresh high at 3,878 points yesterday, and that's helping our bullish position in drugmaker Pfizer (PFE). We are getting close to our target of $34.75 where we plan to take profits. Our single-leg call position closed at $1.67. Investors could set a stop loss at the call's purchase price of $1.10.

— Edited by John Acher

Non-independent investment research disclaimer applies. Read more
A compiled overview of Trade Views provided on is found here
ChristianK ChristianK
Good call so far. I am not able to set a stop loss on the long call option. The platform will only allow input of a take profit / limit price. Is this because the option is already in the money or? Thx
Georgio Stoev Georgio Stoev
oops, we took the type of order out earlier this year. Will re-install soon. In process of creating new algos for various orders.
ChristianK ChristianK
Got it. Thx


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail